Peter Bernhardt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8131035/publications.pdf

Version: 2024-02-01

60	1,726	279798	289244
papers	citations	23	40
		h-index	g-index

62	62	62	1554
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Promising Prospects for ⁴⁴Sc-/⁴⁷Sc-Based Theragnostics: Application of ⁴⁷Sc for Radionuclide Tumor Therapy in Mice. Journal of Nuclear Medicine, 2014, 55, 1658-1664.	5.0	163
2	Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1480-1489.	6.4	144
3	Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1919-1930.	6.4	109
4	Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 476-485.	6.4	86
5	Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 947-955.	6.4	79
6	EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1778-1809.	6.4	70
7	EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres. EJNMMI Physics, 2021, 8, 77.	2.7	61
8	Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy. EJNMMI Physics, 2018, 5, 12.	2.7	60
9	Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617. Scientific Reports, 2019, 9, 17800.	3.3	49
10	Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. International Journal of Radiation Oncology Biology Physics, 2001, 51, 514-524.	0.8	46
11	Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, 569-576.	0.8	45
12	Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo Properties. Molecular Pharmaceutics, 2017, 14, 523-532.	4.6	44
13	Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate. EJNMMI Research, 2016, 6, 13.	2.5	43
14	First-in-Humans Application of ¹⁶¹Tb: A Feasibility Study Using ¹⁶¹Tb-DOTATOC. Journal of Nuclear Medicine, 2021, 62, 1391-1397.	5.0	42
15	Fast GPU-based Monte Carlo code for SPECT/CT reconstructions generates improved 177Lu images. EJNMMI Physics, 2018, 5, 1.	2.7	41
16	Bone Marrow Absorbed Doses and Correlations with Hematologic Response During ¹⁷⁷Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases. Journal of Nuclear Medicine, 2019, 60, 1406-1413.	5.0	41
17	Dosimetric characterization of radionuclides for systemic tumor therapy: Influence of particle range, photon emission, and subcellular distribution. Medical Physics, 2006, 33, 3260-3269.	3.0	40
18	Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy. Nuclear Medicine and Biology, 2015, 42, 770-779.	0.6	38

#	Article	IF	Citations
19	A novel planar image-based method for bone marrow dosimetry in 177Lu-DOTATATE treatment correlates with haematological toxicity. EJNMMI Physics, 2016, 3, 21.	2.7	36
20	NAMPT Inhibitor GMX1778 Enhances the Efficacy of ¹⁷⁷Lu-DOTATATE Treatment of Neuroendocrine Tumors. Journal of Nuclear Medicine, 2017, 58, 288-292.	5.0	33
21	Biodistribution data from 100 patients i.v. injected with111in-DTPA-D-Phe1-Octreotide. Acta OncolÃ³gica, 2004, 43, 436-442.	1.8	30
22	Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3830-3840.	6.4	30
23	Radiation exposure of the spleen during 177Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume. EJNMMI Physics, 2016, 3, 15.	2.7	28
24	Deep-Learning Generation of Synthetic Intermediate Projections Improves ¹⁷⁷Lu SPECT Images Reconstructed with Sparsely Acquired Projections. Journal of Nuclear Medicine, 2021, 62, 528-535.	5.0	25
25	Therapeutic Potential of 47Sc in Comparison to 177Lu and 90Y: Preclinical Investigations. Pharmaceutics, 2019, 11, 424.	4.5	24
26	Biodistribution of 111in-DTPA-D-Phe1-octreotide in tumor-bearing nude mice: influence of amount injected and route of administration. Nuclear Medicine and Biology, 2003, 30, 253-260.	0.6	23
27	Heterogeneity of microsphere distribution in resected liver and tumour tissue following selective intrahepatic radiotherapy. EJNMMI Research, 2014, 4, 48.	2.5	23
28	Model of metastatic growth valuable for radionuclide therapy. Medical Physics, 2003, 30, 3227-3232.	3.0	22
29	Effects of Treatment with 177Lu-DOTA-Tyr3-Octreotate on Uptake of Subsequent Injection in Carcinoid-Bearing Nude Mice. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 644-653.	1.0	22
30	A novel statistical analysis method to improve the detection of hepatic foci of 111In-octreotide in SPECT/CT imaging. EJNMMI Physics, 2016, 3, 1.	2.7	21
31	Increased absorbed liver dose in Selective Internal Radiation Therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneity. EJNMMI Physics, 2015, 2, 10.	2.7	20
32	Establishment of a clinical SPECT/CT protocol for imaging of 161Tb. EJNMMI Physics, 2020, 7, 45.	2.7	20
33	Dosimetric Analysis of the Short-Ranged Particle Emitter 161Tb for Radionuclide Therapy of Metastatic Prostate Cancer. Cancers, 2021, 13, 2011.	3.7	19
34	Promising potential of [177Lu]Lu-DOTA-folate to enhance tumor response to immunotherapyâ€"a preclinical study using a syngeneic breast cancer model. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 984-994.	6.4	16
35	Modelling of metastatic cure after radionuclide therapy: Influence of tumor distribution, cross-irradiation, and variable activity concentration. Medical Physics, 2004, 31, 2628-2635.	3.0	13
36	Intracranial Volume in 15 Children with Bilateral Coronal Craniosynostosis. Plastic and Reconstructive Surgery - Global Open, 2014, 2, e243.	0.6	12

#	Article	IF	Citations
37	Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile. Molecules, 2020, 25, 2542.	3.8	12
38	Pituitary Function after High-Dose ¹⁷⁷Lu-DOTATATE Therapy and Long-Term Follow-Up. Neuroendocrinology, 2021, 111, 344-353.	2.5	12
39	Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3639-3650.	6.4	9
40	A new quantitative image-based method for evaluation of bony temporal hollowing in metopic synostosis. Journal of Plastic Surgery and Hand Surgery, 2016, 50, 343-348.	0.8	7
41	Evaluation of SSTR2 Expression in SI-NETs and Relation to Overall Survival after PRRT. Cancers, 2021, 13, 2035.	3.7	7
42	Radiation exposure during liver surgery after treatment with⁹⁰Y microspheres, evaluated with computer simulations and dosimeter measurements. Journal of Radiological Protection, 2012, 32, 439-446.	1.1	6
43	A Novel Quantitative Image-Based Method for Evaluating Cranial Symmetry and Its Usefulness in Patients Undergoing Surgery for Unicoronal Synostosis. Journal of Craniofacial Surgery, 2013, 24, 166-169.	0.7	6
44	The impact of including spatially longitudinal heterogeneities of vessel oxygen content and vascular fraction in 3D tumor oxygenation models on predicted radiation sensitivity. Medical Physics, 2014, 41, 044101.	3.0	6
45	Segmentation of Whole-Body Images into Two Compartments in Model for Bone Marrow Dosimetry Increases the Correlation with Hematological Response in 177Lu-DOTATATE Treatments. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 335-343.	1.0	6
46	Artificial intelligence and the medical physics profession - A Swedish perspective. Physica Medica, 2021, 88, 218-225.	0.7	6
47	Simulation Model of Microsphere Distribution for Selective Internal Radiation Therapy Agrees With Observations. International Journal of Radiation Oncology Biology Physics, 2016, 96, 414-421.	0.8	5
48	Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute. Pharmaceutics, 2019, 11, 450.	4.5	4
49	Optimizing the Schedule of PARP Inhibitors in Combination with 177Lu-DOTATATE: A Dosimetry Rationale. Biomedicines, 2021, 9, 1570.	3.2	4
50	Oxygen distribution in tumors: A qualitative analysis and modeling study providing a novel Monte Carlo approach. Medical Physics, 2014, 41, 094101.	3.0	3
51	Autoradiography and biopsy measurements of a resected hepatocellular carcinoma treated with 90 yttrium radioembolization demonstrate large absorbed dose heterogeneities. Advances in Radiation Oncology, 2018, 3, 439-446.	1.2	3
52	Re: Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2019, 30, 2047-2048.	0.5	3
53	Evaluation of the Spatial Resolution In monte Carlo-Based Spect/Ct Reconstruction Of 111In-Octreotide Images. Radiation Protection Dosimetry, 2021, 195, 319-326.	0.8	3
54	Activity Concentration Estimation in Automated Kidney Segmentation Based on Convolution Neural Network Method for 177LUâ€“SPECT/CT Kidney Dosimetry. Radiation Protection Dosimetry, 2021, 195, 164-171.	0.8	3

#	Article	IF	Citations
55	IMPROVED PLANAR KIDNEY ACTIVITY CONCENTRATION ESTIMATE BY THE POSTERIOR VIEW METHOD IN177LU-DOTATATE TREATMENTS. Radiation Protection Dosimetry, 2016, 169, 259-266.	0.8	2
56	IMAGE FUSION OF RECONSTRUCTED DIGITAL TOMOSYNTHESIS VOLUMES FROM A FRONTAL AND A LATERAL ACQUISITION. Radiation Protection Dosimetry, 2016, 169, 410-415.	0.8	1
57	OPTIMISATION IN X-RAY AND MOLECULAR IMAGING 2020. Radiation Protection Dosimetry, 2021, 195, 133-133.	0.8	0
58	Oxygen Distributionsâ€"Evaluation of Computational Methods, Using a Stochastic Model for Large Tumour Vasculature, to Elucidate the Importance of Considering a Complete Vascular Network. PLoS ONE, 2016, 11, e0166251.	2.5	0
59	Terbium radionuclides for theranostics. , 2021, , .		0
60	Mars â€“ a target for teachers and science students. Proceedings of the International Astronomical Union, 2019, 15, 449-450.	0.0	0